Medication info
Olplus Tablet

Olplus Tablet

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Korea Prime Pharmaceutical Co., Ltd.
Appearance
Light orange round film-coated tablets
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 201101640 · Approved 2011.03.23 · Insurance code 663604870

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Before administering this medicine, it is recommended that the dosage of olmesartan medoxomil or hydrochlorothiazide be adjusted individually. If blood pressure is not adequately controlled with the individual components, administer 1 tablet of this medicine once daily, with or without food. Adjust the dose at intervals of 2~4 weeks, taking the patient's blood pressure response into consideration. A marked reduction in blood pressure may occur when olmesartan medoxomil is added or patients are switched to this medicine (olmesartan medoxomil/hydrochlorothiazide) if they are taking high-dose hydrochlorothiazide monotherapy or have volume depletion or hyponatremia. In such cases, reduce the hydrochlorothiazide dose to 12.5 mg before adding olmesartan medoxomil. <Elderly patients> Start at the lowest dose in elderly patients. Use caution when adjusting the dose, taking into consideration the patient's renal or cardiac function, comorbidities, and other concomitant medications. <Patients with renal impairment> This medicine (olmesartan medoxomil/hydrochlorothiazide) is generally administered to patients with mild to moderate renal impairment (creatinine clearance>30mL/min). Do not administer this medicine (olmesartan medoxomil/hydrochlorothiazide) to patients with more severe renal impairment, for whom loop diuretics are preferable to thiazide diuretics. <Patients with hepatic impairment> Use of this medicine is not recommended in patients with hepatic impairment because there is no experience with its use in these patients.
Child dose
<Pediatric patients> The safety and efficacy in pediatric patients have not been established.

Ingredients

Manufacturer
Korea Prime Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

Olmesartan medoxomil and hydrochlorothiazide are used together to effectively lower blood pressure when blood pressure is not sufficiently controlled when each is used alone in patients with essential hypertension. This drug combination helps improve blood pressure control by dilating blood vessels and promoting the excretion of body fluids and salt. Therefore, this drug is used for the treatment of essential hypertension.

How to take

Adult dose

Before administering this medicine, it is recommended that the dosage of olmesartan medoxomil or hydrochlorothiazide be adjusted individually. If blood pressure is not adequately controlled with the individual components, administer 1 tablet of this medicine once daily, with or without food. Adjust the dose at intervals of 2~4 weeks, taking the patient's blood pressure response into consideration. A marked reduction in blood pressure may occur when olmesartan medoxomil is added or patients are switched to this medicine (olmesartan medoxomil/hydrochlorothiazide) if they are taking high-dose hydrochlorothiazide monotherapy or have volume depletion or hyponatremia. In such cases, reduce the hydrochlorothiazide dose to 12.5 mg before adding olmesartan medoxomil. <Elderly patients> Start at the lowest dose in elderly patients. Use caution when adjusting the dose, taking into consideration the patient's renal or cardiac function, comorbidities, and other concomitant medications. <Patients with renal impairment> This medicine (olmesartan medoxomil/hydrochlorothiazide) is generally administered to patients with mild to moderate renal impairment (creatinine clearance>30mL/min). Do not administer this medicine (olmesartan medoxomil/hydrochlorothiazide) to patients with more severe renal impairment, for whom loop diuretics are preferable to thiazide diuretics. <Patients with hepatic impairment> Use of this medicine is not recommended in patients with hepatic impairment because there is no experience with its use in these patients.

Child dose

<Pediatric patients> The safety and efficacy in pediatric patients have not been established.

Precautions

This drug can cause serious harm or death to the fetus and newborn during the second and third trimesters of pregnancy, so it should be stopped immediately if pregnancy is confirmed. Patients who are allergic to any of the components of this drug or have hypersensitivity to certain diuretics, those with severe kidney or liver disease, pregnant or nursing mothers, and those with certain genetic metabolic disorders should not take this drug. Patients with decreased blood volume or weakened kidney function, those with liver disease, patients with certain heart diseases, the elderly, and infants need special care and close monitoring when using this drug. This drug lowers blood pressure, which may lead to dizziness or hypotension, so caution is advised when engaging in dangerous activities such as high-altitude work or driving. While taking this drug, electrolyte levels in the blood and kidney function should be regularly monitored for any abnormalities, with particular attention to potassium levels. This drug may interact with other antihypertensive medications, potassium supplements, certain diuretics, and anti-inflammatory analgesics, so patients should inform their healthcare provider of any other medications they are taking. During pregnancy or breastfeeding, it is advisable to avoid this medication or consult a doctor, particularly because adverse reactions may occur in breastfeeding infants. Safety and effectiveness in pediatric patients have not yet been established, so it is recommended not to administer to children. In case of overdose, symptoms such as hypotension, electrolyte imbalances, and dehydration may occur, and immediate medical attention is necessary. If new lesions on the skin appear, or symptoms such as eye pain, vision impairment, or difficulty breathing occur during treatment, the patient should inform their doctor immediately.

Side effects

nausea, hyperuricemia, dizziness, upper respiratory infection, headache, urinary tract infection, chest pain, back pain, peripheral edema, vertigo, abdominal pain, dyspepsia, gastritis, diarrhea, elevated AST, elevated GGT, elevated ALT, hyperlipidemia, elevated creatine phosphokinase, hyperglycemia, arthritis, arthralgia, myalgia, cough, rash, hematuria, facial edema, asthenia, angioedema, anaphylactic reaction, vomiting, rhabdomyolysis, acute renal failure, increased serum creatinine, hair loss, pruritus, urticaria, dyspepsia, hyponatremia, polyuria, palpitations, hypertension, epistaxis, asthma, chronic malabsorption syndrome, intestinal vascular edema, autoimmune hepatitis, palpitations, orthostatic hypotension, arrhythmia, transient visual disturbance, jaundice, choroidal exudate, jaundice, hepatitis, acute cholecystitis, necrotizing vasculitis, interstitial pneumonia, pulmonary edema, dyspnea, weakness, Stevens-Johnson syndrome, erythema multiforme, exfoliative dermatitis, toxic epidermal necrolysis, hypokalemia, hyponatremia, hypomagnesemia, hypochloremic alkalosis, hypercalcemia, anorexia, thirst, abdominal discomfort, constipation, abdominal colic, pancreatitis, jaundice, sialadenitis, dry mouth, fatigue, drowsiness, emotional blunting, restlessness, acute respiratory distress syndrome, thrombocytopenia, leukopenia, aplastic anemia, hemolytic anemia, purpura, malaise, nasal congestion, erectile dysfunction, exacerbation of systemic lupus erythematosus, parathyroid dysfunction, muscle cramps, sensory disturbances

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a tightly closed container to prevent exposure to air or moisture. It is best to maintain a storage temperature between 1 degree and 25 degrees Celsius at room temperature. This helps to maintain the drug's effectiveness for a longer period.

Appearance and packaging

Appearance

Light orange round film-coated tablets

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.